Istituto Ortopedico Rizzoli
Bologna, BO, 40136, Italy
NCT Number: NCT03453372
A double-blind placebo-controlled randomized clinical trial to evaluate the efficacy of magnetic resonance-guided focused ultrasound surgery (MRgFUS) in the treatment of pain caused by knee osteoarthritis (OA)
Looking for future studies?
Notify Me50 year–80 year
All sexes
Interventional
Not applicable
Bologna, BO, 40136, Italy
Osteoarthritis (OA) is a common, disabling, and costly disease, and the knee is one of the most affected joints. The predominant symptom is pain. Effective and lasting non-invasive treatment approaches are missing. MR-guided focused ultrasound surgery (MRgFUS) is a new minimally invasive technique which may represent a valid solution providing several advantages. The primary aim of this work will be to assess the efficacy of MRgFUS in the treatment of pain caused by knee OA in 80 patients candidate for arthroplasty in a prospective, randomized, double-blinded, placebo-controlled clinical trial. Different parameters related to pain, quality of life, function, and imaging will be collected and analyzed in a 12-month follow-up. The secondary aims will be focused on a) the evaluation of the effects on the joint organ and changes of biological features in response to MRgFUS, and b) the impact of selective ablation of nociceptors on OA pain, based on the analysis of resected joint tissues.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Treatment of pain caused by knee osteoarthritis with high-intensity focused ultrasound
Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
Time frame: Baseline (Day 1), 24 hours post MRgFUS, Week 1, 2, 3, Month 1, 3, 6,12
The efficacy of MRgFUS will be demonstrated if the treatment group has a mean reduction of Visual Analog Pain Scale (VAS) of at least 1.5 points greater than the control group.
Time frame: Baseline (Day 1), 24 hours post MRgFUS, Month 1, 3, 6,12
Enzyme linked immuno assays kits will be used to test inflammatory markers in serum. The reference standard values of the standardized markers will be considered for the evaluations.
Time frame: Baseline (Day 1), 24 hours post MRgFUS, Month 1, 3, 6,12
Enzyme linked immuno assays kits will be used to test bone turnover markers in serum. The reference standard values of the standardized markers will be considered for the evaluations.
Time frame: Baseline (Day 1), 24 hours post MRgFUS, Month 1, 3, 6,12
Enzyme linked immuno assays kits will be used to test pain markers in serum. The reference standard values of the standardized markers will be considered for the evaluations.
Time frame: Baseline (Day 1), 24 hours post MRgFUS, Month 1, 3, 6,12
Enzyme linked immuno assays kits will be used to test cartilage turnover markers in urine. The reference standard values of the standardized markers will be considered for the evaluations.
Istituto Ortopedico Rizzoli
Other
Pain in Knee Osteoarthritis, a Placebo-controlled Randomized Clinical Trial for a New Potential Therapeutic Approach: Magnetic Resonance Guided Focused Ultrasound Surgery (MRgFUS)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06032442
Arthritis, Joint Diseases
Saint Petersburg, Sankt-Peterburg, Russia
View Trial DetailsNCT05164575
Arthritis, Hip Osteoarthritis
Edmonton, Alberta, Canada
View Trial DetailsNCT04456569
Arthritis, Joint Diseases
Minneapolis, Minnesota, United States
View Trial DetailsNCT05618782
Arthritis, Connective Tissue Diseases
Brno, Czechia
View Trial Details